Literature DB >> 9708602

Continuous renal replacement therapies: an update.

M Manns1, M H Sigler, B P Teehan.   

Abstract

Continuous renal replacement modalities have found widespread use and acceptance over the last decade. The various modalities differ in the kind of access (arteriovenous v venovenous); in the application of convective clearance (continuous hemofiltration), diffusive clearance (continuous hemodialysis), or a combination of both (continuous hemodiafiltration); and in the location where the replacement fluid enters the circuit (predilution v postdilution). Continuous therapies incorporate several advantages, such as improved hemodynamic stability, the possibility for unlimited alimentation, optimal fluid balance, and gradual urea removal without fluctuations. However, it has not yet been shown whether these advantages have a significant impact on outcome and prognosis, the ultimate measure of treatment efficiency. Major disadvantages of continuous therapies are the ongoing necessity for continuous anticoagulation, immobilization of the patient, and possible side effects from lactate-containing replacement fluid or dialysate. Continuous renal replacement procedures have certainly made the management of critically ill patients easier. In particular, oligoanuric patients with diuretic resistant volume overload and hemodynamically unstable patients with acute renal failure and concomitant sepsis or multiorgan failure appear to benefit most from continuous treatment. The role of continuous hemofiltration as a method of removing serum cytokines in septic patients without renal failure is still controversial and needs further clinical assessment. Due to slow efficacy, continuous renal replacement is indicated only in rare circumstances for intoxication; this therapy also is of rather limited use in severe hyperkalemia or acidosis. Noncritically ill patients with uncomplicated renal failure (eg, due to the use of dye or antibiotics) should be treated with intermittent hemodialysis or peritoneal dialysis. Furthermore, intermittent hemodialysis is preferable in patients with hemorrhagic diathesis because it can be easily performed without anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9708602     DOI: 10.1053/ajkd.1998.v32.pm9708602

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  13 in total

1.  Ureteric morphogenesis requires Fgfr1 and Fgfr2/Frs2α signaling in the metanephric mesenchyme.

Authors:  Sunder Sims-Lucas; Valeria Di Giovanni; Caitlin Schaefer; Brian Cusack; Veraragavan P Eswarakumar; Carlton M Bates
Journal:  J Am Soc Nephrol       Date:  2012-01-26       Impact factor: 10.121

Review 2.  Continuous renal replacement therapies: a brief primer for the neurointensivist.

Authors:  Pritesh Patel; Veena Nandwani; Paul J McCarthy; Steven A Conrad; L Keith Scott
Journal:  Neurocrit Care       Date:  2010-10       Impact factor: 3.210

3.  Using Zero Balance Ultrafiltration with Dialysate as a Replacement Fluid for Hyperkalemia during Cardiopulmonary Bypass.

Authors:  Michele Heath; Karthik Raghunathan; Ian Welsby; Cory Maxwell
Journal:  J Extra Corpor Technol       Date:  2014-09

4.  Physical compatibility of magnesium sulfate and sodium bicarbonate in a pharmacy-compounded hemofiltration solution.

Authors:  Brad Moriyama; Stacey A Henning; Haksong Jin; Michael Kolf; Nadja N Rehak; Robert L Danner; Thomas J Walsh; George J Grimes
Journal:  Am J Health Syst Pharm       Date:  2010-04-01       Impact factor: 2.637

5.  Impact of computerized order entry and pre-mixed dialysis solutions for continuous veno-venous hemodiafiltration on selection of therapy for acute renal failure.

Authors:  Lawand Saadulla; W Brian Reeves; Brittany Irey; Nasrollah Ghahramani
Journal:  J Med Syst       Date:  2010-03-26       Impact factor: 4.460

Review 6.  [Acute renal failure and sepsis : Just an organ dysfunction due to septic multiorgan failure?].

Authors:  C Schmidt; T Steinke; S Moritz; B M Graf; M Bucher
Journal:  Anaesthesist       Date:  2010-08       Impact factor: 1.041

7.  Citrate anticoagulation in pediatric continuous venovenous hemofiltration.

Authors:  Nahum Elhanan; Peter Skippen; Gabrielle Nuthall; Gordon Krahn; Michael Seear
Journal:  Pediatr Nephrol       Date:  2003-12-11       Impact factor: 3.714

8.  Using continuous renal replacement therapy to manage patients of shock and acute renal failure.

Authors:  Sachin S Soni; Amit P Nagarik; Gopal Kishan Adikey; Anuradha Raman
Journal:  J Emerg Trauma Shock       Date:  2009-01

Review 9.  Drug dosing during intermittent hemodialysis and continuous renal replacement therapy : special considerations in pediatric patients.

Authors:  Michael A Veltri; Alicia M Neu; Barbara A Fivush; Rulan S Parekh; Susan L Furth
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Metastatic testicular cancer presenting with liver and kidney dysfunction treated with modified BEP chemotherapy combined with continuous hemodiafiltration and rasburicase.

Authors:  Mai Kimakura; Toyofumi Abe; Akira Nagahara; Kazutoshi Fujita; Hiroshi Kiuchi; Motohide Uemura; Norio Nonomura
Journal:  Anticancer Drugs       Date:  2016-04       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.